Screener
RxSight, Inc. RXST License And Collaboration Revenue — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by RxSight, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: RxSight, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335153
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Product sales | $27,241 | $33,637 | $58,134 | $71,531 |
| License and collaboration revenue | 6,500 | — | 6,500 | — |
| Total revenue | 33,741 | 33,637 | 64,634 | 71,531 |
| Costs and expenses: | ||||
| Cost of sales | 7,855 | 8,447 | 15,250 | 18,013 |
| Selling, general and administrative | 30,419 | 28,976 | 62,274 | 57,611 |
| Research and development | 9,237 | 10,217 | 18,709 | 20,584 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is RxSight, Inc.'s license and collaboration revenue — revenue?
- RxSight, Inc. (RXST) reported license and collaboration revenue — revenue of $6.5M in Q2 2026.
- What does license and collaboration revenue — revenue mean?
- This metric represents revenue generated from licensing intellectual property, technology access, or collaborative research and development agreements with third-party partners. It reflects the company's ability to monetize its proprietary medical technology assets beyond direct product sales. Investors use this to assess the value of the company's innovation pipeline and the strategic success of its partnership-based business model.
Ask your AI about RxSight, Inc.'s license and collaboration revenue — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude